Strategies for Targeting Mitochondria in the Treatment of Breast Cancer

IF 3.7 Q1 CHEMISTRY, MEDICINAL

ACS Pharmacology and Translational Science Pub Date : 2026-08-14 Epub Date: 2026-07-02 DOI:10.1021/acsptsci.5c00823

Kexin Wang, Xianyi Zheng, Yating Li, Chunyan Li, Xiaoyong Zhang, Qichuan Deng, Hao Yang, Xiaocui Shuai, Jinqi Li, Li Guo, Jianyou Shi, Lan Bai

{"title":"Strategies for Targeting Mitochondria in the Treatment of Breast Cancer","authors":"Kexin Wang, Xianyi Zheng, Yating Li, Chunyan Li, Xiaoyong Zhang, Qichuan Deng, Hao Yang, Xiaocui Shuai, Jinqi Li, Li Guo, Jianyou Shi, Lan Bai","doi":"10.1021/acsptsci.5c00823","DOIUrl":null,"url":null,"abstract":"<p>Breast cancer is the most prevalent cancer among women\r\nworldwide,\r\nwith a complex pathogenesis and diverse treatment options. However,\r\nconventional treatments are often accompanied by large side effects\r\nand limited efficacy. In recent years, mitochondria, as the core organelles\r\nof cellular energy metabolism, oxidative stress regulation, and apoptosis\r\nexecution, have played a key role in breast cancer development, progression,\r\nmetastasis, and treatment resistance. Therefore, many researchers\r\nhave turned their attention to mitochondria to open up new pathways\r\nfor the treatment of breast cancer. This review systematically outlines\r\nthe relationship between mitochondrial energy metabolism, antiapoptotic\r\nproteins, mitochondrial fusion/fission, mitochondrial autophagy, and\r\nferroptosis and breast cancer cell proliferation, metastasis, and\r\ndrug resistance, summarizes and analyzes the inhibitory effects of\r\ndrugs or therapeutics targeting mitochondria, and explores the strategies\r\nof targeting mitochondria for the treatment of breast cancer to provide\r\nnew ideas and methods for the treatment of breast cancer.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"9 8","pages":"2008–2023"},"PeriodicalIF":3.7000,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsptsci.5c00823","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer is the most prevalent cancer among women worldwide, with a complex pathogenesis and diverse treatment options. However, conventional treatments are often accompanied by large side effects and limited efficacy. In recent years, mitochondria, as the core organelles of cellular energy metabolism, oxidative stress regulation, and apoptosis execution, have played a key role in breast cancer development, progression, metastasis, and treatment resistance. Therefore, many researchers have turned their attention to mitochondria to open up new pathways for the treatment of breast cancer. This review systematically outlines the relationship between mitochondrial energy metabolism, antiapoptotic proteins, mitochondrial fusion/fission, mitochondrial autophagy, and ferroptosis and breast cancer cell proliferation, metastasis, and drug resistance, summarizes and analyzes the inhibitory effects of drugs or therapeutics targeting mitochondria, and explores the strategies of targeting mitochondria for the treatment of breast cancer to provide new ideas and methods for the treatment of breast cancer.

查看原文本刊更多论文

靶向线粒体治疗乳腺癌的策略

乳腺癌是世界范围内最常见的女性癌症，其发病机制复杂，治疗方案多样。然而，传统的治疗方法往往伴随着巨大的副作用和有限的疗效。近年来，线粒体作为细胞能量代谢、氧化应激调节和细胞凋亡执行的核心细胞器，在乳腺癌的发生、进展、转移和治疗耐药中发挥了关键作用。因此，许多研究者将注意力转向了线粒体，以期为乳腺癌的治疗开辟新的途径。本文系统地综述了线粒体能量代谢、抗凋亡蛋白、线粒体融合/裂变、线粒体自噬、凋亡与乳腺癌细胞增殖、转移、耐药的关系，总结和分析了靶向线粒体的药物或治疗方法的抑制作用。并探索靶向线粒体治疗乳腺癌的策略，为乳腺癌的治疗提供新的思路和方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Pharmacology and Translational Science Medicine-Pharmacology (medical)

CiteScore

10.00

自引率

3.30%

发文量

133

期刊介绍： ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered. ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition. Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.